Related content

Bone resorption starts at 14 days of treatment with gonadotropin-releasing hormone agonist in in vitro fertilization cycles

By Yilmaz H   Ozgur K   Isikoglu M   Sonmez C   Uner M  

Gynecological Endocrinology, Vol. 19, Iss. 1, 2004-07 ,pp. : 40-46

Informa Healthcare

Access to resources Recommend Favorite

Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature

By Pinto Evelin   Pinelo Sueli   Osório Marta   Ferreira Carla   Serra Helena   Pires Ilda   Barbosa António   Figueiredo Helena   Felgueira Eduarda   Tavares Angelina  

Gynecological Endocrinology, Vol. 28, Iss. 7, 2012-07 ,pp. : 545-548

Informa Healthcare

Access to resources Recommend Favorite

Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer

By Onagawa T   Shibahara H     Machida S   Hirano Y   Hirashima C   Takamizawa S   Suzuki M  

Gynecological Endocrinology, Vol. 18, Iss. 6, 2004-06 ,pp. : 335-340

Informa Healthcare

Access to resources Recommend Favorite

Genetic screening in Italian infertile couples undergoing intrauterine insemination and in vitro fertilization techniques: a multicentric study

By Artini Paolo Giovanni   Papini Francesca   Ruggiero Maria   Bartalini Gabriella   De Leo Vincenzo   Scaravelli Giulia   Piomboni Paola   Cela Vito  

Gynecological Endocrinology, Vol. 27, Iss. 7, 2011-07 ,pp. : 453-457

Informa Healthcare

Access to resources Recommend Favorite

Relationship between gonadotropin releasing hormone agonist dosage and in vitro fertilization outcome

By Lorusso F.   Depalo R.   Selvaggi L.  

Gynecological Endocrinology, Vol. 18, Iss. 2, 2004-01 ,pp. : 69-73

Informa Healthcare

Access to resources Recommend Favorite